Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.

BACKGROUND Ranolazine is evaluated for antiarrhythmic therapy of atrial fibrillation (AF). The electrophysiologic mechanisms of ranolazine in combination with class III drugs were studied in an isolated whole-heart model of stretch-related AF. METHODS AND RESULTS Thirty rabbits were fed with amiodarone (50 mg/kg/day, n = 10), dronedarone (50 mg/kg/day, n = 10), or placebo (n = 10) for 6 weeks. Subsequently, in isolated hearts, AF was induced by high-rate atrial pacing and acute atrial dilatation. In placebo-treated hearts, d,l-sotalol (50 μM) was acutely administered. Ranolazine (10 μM) was additionally infused in all groups. Chronic amiodarone (+26 ± 7 ms, P < 0.05) or dronedarone (+22 ± 4 ms, P < 0.05) as well as acute application of d,l-sotalol (+20 ± 3 ms, P < 0.05) increased atrial action potential duration (aAPD90 ). Additional treatment with ranolazine did not significantly change aAPD90 (P = ns). Class III drugs did not affect interatrial conduction time, while ranolazine significantly increased it (amiodarone group: +15 ± 3 ms, dronedarone group: +11 ± 3 ms, sotalol group: +15 ± 6 ms; P < 0.05 each). Ranolazine led to an additional increase in atrial effective refractory period (aERP), thus leading to an enhanced atrial postrepolarization refractoriness (aPRR, +17 ± 6 ms, +21 ± 4 ms and +16 ± 8 ms, P < 0.05, respectively). Acute atrial dilatation increased AF incidence compared with baseline. Amiodarone-pretreated hearts showed a lower incidence of AF. Additional infusion of ranolazine further diminished AF. Dronedarone or acute infusion of sotalol did not significantly suppress AF, while additional treatment with ranolazine in these groups also reduced AF incidence. CONCLUSION In this study, ranolazine on top of class III antiarrhythmic therapy had a beneficial effect. The increase in interatrial conduction time and marked atrial aPRR suppressed AF. These results shed further light on a potential therapeutic benefit of ranolazine on top of conventional antiarrhythmic therapy for rhythm control in AF.

[1]  G. Breithardt,et al.  Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  G. Breithardt,et al.  Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. , 2012, Heart rhythm.

[3]  K. Koskinas,et al.  Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. , 2012, The American journal of cardiology.

[4]  G. Breithardt,et al.  Electrophysiologic Profile of Dronedarone on the Ventricular Level: Beneficial Effect on Postrepolarization Refractoriness in the Presence of Rapid Phase 3 Repolarization , 2012, Journal of cardiovascular pharmacology.

[5]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[6]  K. Wasmer,et al.  Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  G. Breithardt,et al.  A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase‐III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing‐induced heart failure , 2011, European journal of heart failure.

[8]  R. Passman,et al.  Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. , 2011, The American journal of cardiology.

[9]  C. Antzelevitch,et al.  Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. , 2011, American journal of physiology. Heart and circulatory physiology.

[10]  Charles Antzelevitch,et al.  Electrophysiologic basis for the antiarrhythmic actions of ranolazine. , 2011, Heart rhythm.

[11]  Charles Antzelevitch,et al.  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[12]  Stefan Wagner,et al.  Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. , 2010, Journal of the American College of Cardiology.

[13]  Charles Antzelevitch,et al.  Synergistic Electrophysiologic and Antiarrhythmic Effects of the Combination of Ranolazine and Chronic Amiodarone in Canine Atria , 2010, Circulation. Arrhythmia and electrophysiology.

[14]  V. Hasselblad,et al.  Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[15]  Kapil Kumar,et al.  Ranolazine Exerts Potent Effects on Atrial Electrical Properties and Abbreviates Atrial Fibrillation Duration in the Intact Porcine Heart , 2009, Journal of cardiovascular electrophysiology.

[16]  E. Braunwald,et al.  Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. , 2009, Journal of the American College of Cardiology.

[17]  D. Murdock,et al.  The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation , 2008, Indian pacing and electrophysiology journal.

[18]  C. Antzelevitch,et al.  Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. , 2008, Heart rhythm.

[19]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[20]  Andrew C. Zygmunt,et al.  Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine , 2007, Circulation.

[21]  G. Breithardt,et al.  Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome , 2007, Journal of cardiovascular electrophysiology.

[22]  J. Deharo,et al.  Anti-arrhythmic Effects of INa, IKr, and Combined IKr–ICaL Blockade in an Experimental Model of Acute Stretch-Related Atrial Fibrillation , 2007, Cardiovascular Drugs and Therapy.

[23]  G. Breithardt,et al.  Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation , 2005, Basic Research in Cardiology.

[24]  Ulrich Schotten,et al.  Synergistic Action of Atrial Dilation and Sodium Channel Blockade on Conduction in Rabbit Atria , 2004, Journal of cardiovascular electrophysiology.

[25]  Milan Stengl,et al.  Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.

[26]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[27]  S. Nattel,et al.  Intra-Atrial Pressure Increases Rate and Organization of Waves Emanating From the Superior Pulmonary Veins During Atrial Fibrillation , 2003, Circulation.

[28]  Affirm Investigators.  Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. , 2003, Journal of the American College of Cardiology.

[29]  F. Ravelli.  Mechano-electric feedback and atrial fibrillation. , 2003, Progress in biophysics and molecular biology.

[30]  G. Breithardt,et al.  Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[31]  U. Schotten,et al.  Verapamil Prevents Stretch‐Induced Shortening of Atrial Effective Refractory Period in Langendorff‐Perfused Rabbit Heart , 2001, Journal of cardiovascular electrophysiology.

[32]  J Toyama,et al.  Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. , 1999, The American journal of cardiology.

[33]  P. Kirchhof,et al.  Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. , 1998, Circulation.

[34]  M. Allessie,et al.  Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. , 1997, Circulation.

[35]  Donghee Kim,et al.  Activation of a nonselective cation channel by swelling in atrial cells , 1993, The Journal of Membrane Biology.

[36]  D. Kim,et al.  A mechanosensitive K+ channel in heart cells. Activation by arachidonic acid , 1992, The Journal of general physiology.

[37]  I. Watanabe,et al.  Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. , 2001, Japanese circulation journal.

[38]  M. Turina,et al.  Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure , 1998, European Journal of Clinical Pharmacology.